| Trial Name | Description |
| DeLLphi-305 SCLC |
Dr. D. Breadner Not open yet - A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) |
| ENDO-SABR NSCLC |
Dr. Inderdeep Dhaliwal Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR) |
| PACIFIC 9 NSCLC |
Dr. M. Vincent A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer |
| SKYSCRAPER 06 NSCLC |
Dr. M. Vincent A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previo |
| RESPIRE-ILD Lung |
Dr. D. Palma Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease (RESPIRE-ILD): A 2x2 Factorial Randomized Phase II Trial testing N-Acetyl Cysteine and Dexamethasone |
| eVOLVE-Meso |
Dr. M. Vincent A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural |
| SKYLITE SLC-391-102 NSCLC |
Dr. Daniel Breadner A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). |
| DeLLphi-304 SCLC |
Dr. D. Breadner A Randomized, Open-Label, Phase 3 Study of Tarlatamab Compared with Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy |
| FORTITUDE 102 Gastric-GEJ |
Dr. M. Vincent A Phase 1B/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2B Overexpression |
| Dizal DZ2022E0005 NSCLC |
Dr. J. Raphael A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Facto |
| OCELOT NSCLC |
Dr. M. Vincent Osimertinib then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-Line Rechallenge |
| HARMONi-3 NSCLC |
Dr. S. Kuruvilla A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer |
| IND.242 |
Dr. Daniel Breadner "Not Open Yet" - Neoadjuvant Platform Trial in Patients with Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). |